Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662102 | 0.89 | ALDH1A1 (0.43) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL25203219 | 0.85 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL13636610 | 0.85 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL15125809 | 0.85 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL6496032 | 0.83 | USP2 (0.39) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL576285 | 0.83 | ALDH1A1 (0.39) | ALDH1A1USP2TSHRKDM4ELMNA | |
| SCHEMBL7481663 | 0.81 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL25763314 | 0.81 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL14779809 | 0.81 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL27627837 | 0.79 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606030-B1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LTD (IN) | 2016-05-18 | — | — | EP | claimed |
| US-9240614-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2579377-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| CN-1194960-C | Method for preparing 4,5-diamino shikimic acid derivative | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | disclosed |
| EP-1146036-B1 | Tamiflu, Gallocarboxylic acid approach | HOFFMANN LA ROCHE (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-6518048-B2 | Hydrogenation a isophthalic acid derivative | HOFFMANN-LA ROCHE INC. | 2003-02-11 | — | — | US | disclosed |
| US-20010036653-A1 | Stereo-specific synthesis of shimikic acid derivatives with improved efficiency | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | US | disclosed |
| EP-1146036-A2 | Tamiflu, Gallocarboxylic acid approach | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-17 | — | — | EP | disclosed |
| CN-1317481-A | Method for preparing 4,5-diamino shikimic acid derivative | HOFFMANN LA ROCHE (CH) | 2001-10-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036653-A1 | Stereo-specific synthesis of shimikic acid derivatives with improved efficiency | DDC, ACE, NEU1 | ALDH1A1 299/4885USP2 2953/4885TSHR 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.